NZ610826A - Compositons and methods for targeting type 1 interferon producing cells - Google Patents

Compositons and methods for targeting type 1 interferon producing cells

Info

Publication number
NZ610826A
NZ610826A NZ610826A NZ61082611A NZ610826A NZ 610826 A NZ610826 A NZ 610826A NZ 610826 A NZ610826 A NZ 610826A NZ 61082611 A NZ61082611 A NZ 61082611A NZ 610826 A NZ610826 A NZ 610826A
Authority
NZ
New Zealand
Prior art keywords
immunoglobulin
compositons
methods
producing cells
binds
Prior art date
Application number
NZ610826A
Other languages
English (en)
Inventor
Con Panousis
Eugene Maraskovsky
Nick Wilson
Gino Luigi Vairo
Samantha Busfield
Andrew Nash
Original Assignee
Csl Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44482392&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ610826(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US12/707,297 external-priority patent/US20100209341A1/en
Application filed by Csl Ltd filed Critical Csl Ltd
Publication of NZ610826A publication Critical patent/NZ610826A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ610826A 2010-02-17 2011-02-17 Compositons and methods for targeting type 1 interferon producing cells NZ610826A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12/707,297 US20100209341A1 (en) 2009-02-18 2010-02-17 Treatment of chronic inflammatory conditions
US37448910P 2010-08-17 2010-08-17
US37449710P 2010-08-17 2010-08-17
NZ601760A NZ601760A (en) 2010-02-17 2011-02-17 Compositions and methods for targeting type 1 interferon producing cells

Publications (1)

Publication Number Publication Date
NZ610826A true NZ610826A (en) 2015-01-30

Family

ID=44482392

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ610826A NZ610826A (en) 2010-02-17 2011-02-17 Compositons and methods for targeting type 1 interferon producing cells
NZ601760A NZ601760A (en) 2010-02-17 2011-02-17 Compositions and methods for targeting type 1 interferon producing cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ601760A NZ601760A (en) 2010-02-17 2011-02-17 Compositions and methods for targeting type 1 interferon producing cells

Country Status (10)

Country Link
EP (1) EP2536430B1 (enExample)
JP (1) JP6018507B2 (enExample)
KR (1) KR101842907B1 (enExample)
CN (1) CN103002913B (enExample)
AU (1) AU2011217728B2 (enExample)
CA (1) CA2789810C (enExample)
ES (1) ES2618562T3 (enExample)
IL (1) IL221504B (enExample)
NZ (2) NZ610826A (enExample)
WO (1) WO2011100786A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100209341A1 (en) 2009-02-18 2010-08-19 Csl Limited Treatment of chronic inflammatory conditions
EP2839842A1 (en) * 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
EP3812398A3 (en) 2015-01-23 2021-07-21 Sanofi Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
TW201709932A (zh) 2015-06-12 2017-03-16 西雅圖遺傳學公司 Ｃｄ１２３抗體及其共軛物
US11499168B2 (en) * 2016-04-25 2022-11-15 Universitat Basel Allele editing and applications thereof
MX2021003543A (es) * 2018-09-27 2021-06-23 Xilio Dev Inc Polipeptidos de citocinas enmascaradas.
JP2023553323A (ja) 2020-11-25 2023-12-21 エクシリオ デベロップメント， インコーポレイテッド 腫瘍特異的に切断可能なリンカー
AU2021414400A1 (en) 2020-12-31 2023-08-17 Innate Pharma Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123
CN119365495A (zh) 2022-05-27 2025-01-24 赛诺菲 与NKp46和BCMA变体结合的具有Fc工程化的自然杀伤（NK）细胞接合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002090510A2 (en) * 2001-05-08 2002-11-14 Emory University Regulating immine responses using dendritic cells
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US7763242B2 (en) * 2006-09-07 2010-07-27 Scott and White Memorial Hospital Methods for treating myelodysplastic syndrome with a human interleukin-3-diphtheria toxin conjugate
JP2008162954A (ja) * 2006-12-28 2008-07-17 Kirin Pharma Co Ltd 形質細胞様樹状細胞特異的膜分子に対する抗体を含む治療剤
WO2008127735A1 (en) * 2007-04-13 2008-10-23 Stemline Therapeutics, Inc. Il3ralpha antibody conjugates and uses thereof
EP2231187A4 (en) * 2007-12-06 2013-02-20 Csl Ltd PROCESS FOR SUPPRESSING LEUKEMIA STEM CELLS
US20100209341A1 (en) * 2009-02-18 2010-08-19 Csl Limited Treatment of chronic inflammatory conditions

Also Published As

Publication number Publication date
KR101842907B1 (ko) 2018-03-28
IL221504B (en) 2019-06-30
JP2013519690A (ja) 2013-05-30
CA2789810C (en) 2020-12-01
AU2011217728B2 (en) 2013-03-14
NZ601760A (en) 2013-10-25
CA2789810A1 (en) 2011-08-25
CN103002913B (zh) 2015-12-16
AU2011217728A1 (en) 2012-09-06
EP2536430A1 (en) 2012-12-26
EP2536430A4 (en) 2013-09-04
EP2536430B1 (en) 2016-12-14
ES2618562T3 (es) 2017-06-21
WO2011100786A1 (en) 2011-08-25
KR20130004576A (ko) 2013-01-11
JP6018507B2 (ja) 2016-11-02
CN103002913A (zh) 2013-03-27

Similar Documents

Publication Publication Date Title
NZ601760A (en) Compositions and methods for targeting type 1 interferon producing cells
MX2012011840A (es) Estructuras multimericas especificas para ligado inductor de apoptosis relacionada con el factor de necrosis tumoral r2 (trial).
NZ586053A (en) Anti-vegf antibody compositions and methods
WO2013063419A3 (en) A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
MX2014001371A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
MY183977A (en) Cytotoxic benzodiazepine derivatives
MX2016000722A (es) Miembros de la familia tnf modificados dirigidos.
MX2014001374A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
NZ721184A (en) Therapeutic peptides
MX348579B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
NZ629296A (en) Humanized antibodies that recognize alpha-synuclein
NZ607996A (en) Substituted nucleotide analogs
EP3974453A3 (en) Agents and methods for treating diseases that correlate with bcma expression
WO2011083150A3 (en) Obesity small molecules
EA201590207A1 (ru) Композиции и способы регуляции car-т-клеток
HK1216850A1 (zh) 抗ntb-a抗體及相關的組合物和方法
NZ812025A (en) Polypeptide variants and uses thereof
NZ599737A (en) Il-17a antagonists
WO2012064806A3 (en) Methods and compositions for unsilencing imprinted genes
IN2014CN04648A (enExample)
PH12013502144A1 (en) Multiple myeloma treatment
HRP20171964T1 (hr) Kombinacije i njihova upotreba
NZ602720A (en) Humanized il-25 antibodies

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 17 FEB 2018 BY FB RICE

Effective date: 20150512

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 FEB 2019 BY CPA GLOBAL(PATRAFEE) AB

Effective date: 20180124

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 FEB 2020 BY CPA GLOBAL(PATRAFEE) AB

Effective date: 20190209

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 FEB 2021 BY CPA GLOBAL (PATRAFEE) AB

Effective date: 20200117

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 FEB 2022 BY CPA GLOBAL

Effective date: 20201231

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 FEB 2023 BY CPA GLOBAL

Effective date: 20220107

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 FEB 2024 BY CPA GLOBAL

Effective date: 20230112

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 FEB 2025 BY CPA GLOBAL

Effective date: 20240104

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 FEB 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250102